STAT+: Who will get the first psychedelic approved?

The biotech Compass Pathways has been seen as one of the frontrunners in the race to get the first psychedelic drug approved.

By ChenNov 3, 2026

Score█████░░░░░5.1

VerdictCompetent work. Briefs at most.

Read at STAT

Summary from the source

The biotech Compass Pathways has been seen as one of the frontrunners in the race to get the first psychedelic drug approved. But it could be a tight race, with a non-profit…

Elaine Chen

The editor's rubric

Heuristic review

Leverage2 / 5: Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).; 15% of this desk’s rubric
Magnitude2 / 5: Solid incremental gain on a meaningful problem.; 20% of this desk’s rubric
Evidence2 / 5: Limited: single setting, weak baselines, or an observational association presented as causal.; 20% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 10% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 10% of this desk’s rubric
Stakes2 / 5: Benefits a professional community (practitioners, clinicians, engineers).; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	██░░░2/5	15%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	██░░░2/5	20%	Solid incremental gain on a meaningful problem.
Evidence	██░░░2/5	20%	Limited: single setting, weak baselines, or an observational association presented as causal.
Novelty	██░░░2/5	10%	A new combination of known ideas.
Trajectory	██░░░2/5	10%	Some room to improve with obvious engineering.
Stakes	██░░░2/5	25%	Benefits a professional community (practitioners, clinicians, engineers).

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars).

How the score was computed

rank-2026-10-18

Score█████░░░░░5.1

Score = 10 × (50% × adjusted merit / 10 + 25% × attention + 25% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 3.4 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 3.8 / 10; Shrunk toward the desk prior by editor confidence (30%).
Attention: 28%; Citations, upvotes, points, mentions.
Freshness: 99%; Half-life decay since publication.

No attention signals recorded yet.

The record

Reviewed by heuristic-v10 on Nov 3, 2026, 15:48 UTC. Paper type: news.
Categories: Biotech, Business, Pharma, The Readout, biotechnology, Clinical trials, drug development, Drug prices, FDA, Mental Health
BRIEF, No.1 in the Front page edition of November 3, 2026.
LEAD, No.1 in the News edition of November 3, 2026.